Tofacitinib: Janus bifrons in ulcerative colitis treatment

Gastroenterology

Volumn 144, Issue 5, 2013, Pages 1136-1138

  Peyrin Biroulet, Laurent ^a   Danese, Silvio ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; PREDNISONE; TOFACITINIB;

ADVERSE OUTCOME; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; HUMAN; INFECTION; INFLUENZA; MULTICENTER STUDY; NOTE; PERIANAL ABSCESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SIGMOIDOSCOPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84876495103     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.03.036     Document Type: Note

References (0)